{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:27:56Z","timestamp":1790785676450,"version":"4.1.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Before the advent of effective iron chelation, death from iron-induced cardiomyopathy occurred in the second decade in patients with transfusion-dependent chronic anemias. The advances in our understanding of iron metabolism; the ability to monitor iron loading in the liver, heart, pancreas and pituitary; and the availability of several effective iron chelators have dramatically improved survival and reduced morbidity from transfusion-related iron overload. Nevertheless, significantly increased survival brings about new complications such as malignant transformation resulting from prolonged exposure to iron, which need to be considered when developing long-term therapeutic strategies. This review discusses the current biology of iron homeostasis and its close relation to marrow activity in patients with transfusion-dependent anemias, and how biology informs clinical approach to treatment.<\/jats:p>","DOI":"10.1182\/hematology.2019000036","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T15:12:52Z","timestamp":1575645172000},"page":"337-344","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":55,"title":["Iron overload in transfusion-dependent patients"],"prefix":"10.1182","volume":"2019","author":[{"given":"Thomas D.","family":"Coates","sequence":"first","affiliation":[{"name":"Hematology Section, Children\u2019s Center for Cancer, Blood Diseases and Bone Marrow Transplantation, Children\u2019s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019120610101639500_B1","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/0002-9343(68)90069-7","article-title":"Body iron excretion in man: a collaborative study","volume":"45","author":"Green","year":"1968","journal-title":"Am J Med"},{"issue":"1","key":"2019120610101639500_B2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1532-429X-10-42","article-title":"Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance","volume":"10","author":"Modell","year":"2008","journal-title":"J Cardiovasc Magn Reson"},{"issue":"6322","key":"2019120610101639500_B3","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/bmj.284.6322.1081","article-title":"Survival and desferrioxamine in thalassaemia major","volume":"284","author":"Modell","year":"1982","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"1","key":"2019120610101639500_B4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/nyas.13060","article-title":"Management of iron overload in hemoglobinopathies: what is the appropriate target iron level?","volume":"1368","author":"Coates","year":"2016","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"2019120610101639500_B5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJM200008033430503","article-title":"Hepatic iron concentration and total body iron stores in thalassemia major","volume":"343","author":"Angelucci","year":"2000","journal-title":"N Engl J Med"},{"issue":"3","key":"2019120610101639500_B6","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2141.2004.05202.x","article-title":"Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance","volume":"127","author":"Anderson","year":"2004","journal-title":"Br J Haematol"},{"issue":"2","key":"2019120610101639500_B7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/ajh.22247","article-title":"Pituitary iron and volume predict hypogonadism in transfusional iron overload","volume":"87","author":"Noetzli","year":"2012","journal-title":"Am J Hematol"},{"key":"2019120610101639500_B8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.freeradbiomed.2014.03.039","article-title":"Physiology and pathophysiology of iron in hemoglobin-associated diseases","volume":"72","author":"Coates","year":"2014","journal-title":"Free Radic Biol Med"},{"issue":"4","key":"2019120610101639500_B9","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1152\/physrev.00008.2013","article-title":"Systemic iron homeostasis","volume":"93","author":"Ganz","year":"2013","journal-title":"Physiol Rev"},{"issue":"7","key":"2019120610101639500_B10","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1182\/blood-2002-10-3235","article-title":"Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein","volume":"101","author":"Nemeth","year":"2003","journal-title":"Blood"},{"issue":"5","key":"2019120610101639500_B11","doi-asserted-by":"crossref","first-page":"a011668","DOI":"10.1101\/cshperspect.a011668","article-title":"Iron metabolism: interactions with normal and disordered erythropoiesis","volume":"2","author":"Ganz","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"5","key":"2019120610101639500_B12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1600-0609.2009.01310.x","article-title":"Non-transferrin-bound iron in haematological patients during chemotherapy and conditioning for autologous stem cell transplantation","volume":"83","author":"Sahlstedt","year":"2009","journal-title":"Eur J Haematol"},{"issue":"11","key":"2019120610101639500_B13","doi-asserted-by":"crossref","first-page":"E283","DOI":"10.1002\/ajh.23543","article-title":"Tissue iron evaluation in chronically transfused children shows significant levels of iron loading at a very young age","volume":"88","author":"Berdoukas","year":"2013","journal-title":"Am J Hematol"},{"key":"2019120610101639500_B14","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.freeradbiomed.2013.09.001","article-title":"The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress","volume":"65","author":"Koskenkorva-Frank","year":"2013","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"2019120610101639500_B15","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1182\/blood.V88.2.705.bloodjournal882705","article-title":"Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy","volume":"88","author":"Porter","year":"1996","journal-title":"Blood"},{"issue":"3","key":"2019120610101639500_B16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/CIR.0b013e31829b2be6","article-title":"Cardiovascular function and treatment in \u03b2-thalassemia major: a consensus statement from the American Heart Association","volume":"128","author":"Pennell","year":"2013","journal-title":"Circulation"},{"issue":"6","key":"2019120610101639500_B17","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/ajh.21416","article-title":"Nutritional deficiencies in iron overloaded patients with hemoglobinopathies","volume":"84","author":"Claster","year":"2009","journal-title":"Am J Hematol"},{"issue":"20","key":"2019120610101639500_B18","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1161\/CIRCULATIONAHA.109.874487","article-title":"Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major","volume":"120","author":"Kirk","year":"2009","journal-title":"Circulation"},{"issue":"3","key":"2019120610101639500_B19","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2141.2009.07970.x","article-title":"Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major","volume":"148","author":"Farmaki","year":"2010","journal-title":"Br J Haematol"},{"key":"2019120610101639500_B20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.freeradbiomed.2014.10.861","article-title":"Iron toxicity and its possible association with treatment of Cancer: lessons from hemoglobinopathies and rare, transfusion-dependent anemias","volume":"79","author":"Puliyel","year":"2015","journal-title":"Free Radic Biol Med"},{"issue":"11","key":"2019120610101639500_B21","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1136\/jech-2014-205075","article-title":"Thalassaemia and risk of cancer: a population-based cohort study","volume":"69","author":"Chung","year":"2015","journal-title":"J Epidemiol Community Health"},{"issue":"3","key":"2019120610101639500_B22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3109\/03630269.2010.484963","article-title":"The 18th ICOC Proceedings in Athens, Greece: New breakthrough in thalassemia leading to the complete treatment of iron overload and to hundreds of patients achieving and maintaining normal body iron stores. Ethical questions on chelation therapy","volume":"34","author":"Kontoghiorghes","year":"2010","journal-title":"Hemoglobin"},{"issue":"4","key":"2019120610101639500_B23","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2141.2010.08229.x","article-title":"New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores","volume":"150","author":"Kolnagou","year":"2010","journal-title":"Br J Haematol"},{"issue":"5","key":"2019120610101639500_B24","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/bjh.14575","article-title":"How we manage iron overload in sickle cell patients","volume":"177","author":"Coates","year":"2017","journal-title":"Br J Haematol"},{"issue":"1","key":"2019120610101639500_B25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/bjh.13374","article-title":"Estimating tissue iron burden: current status and future prospects","volume":"170","author":"Wood","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"2019120610101639500_B26","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/ajh.23650","article-title":"Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload","volume":"89","author":"Puliyel","year":"2014","journal-title":"Am J Hematol"},{"issue":"2","key":"2019120610101639500_B27","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/bjh.13119","article-title":"Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia","volume":"168","author":"Taher","year":"2015","journal-title":"Br J Haematol"},{"issue":"3","key":"2019120610101639500_B28","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1046\/j.1365-2141.2001.02820.x","article-title":"Non-transferrin-bound iron during allogeneic stem cell transplantation","volume":"113","author":"Sahlstedt","year":"2001","journal-title":"Br J Haematol"},{"issue":"1","key":"2019120610101639500_B29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ejh.12540","article-title":"Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment","volume":"96","author":"Porter","year":"2016","journal-title":"Eur J Haematol"},{"issue":"1","key":"2019120610101639500_B30","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3324\/haematol.2015.133983","article-title":"Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders","volume":"101","author":"de Swart","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"2019120610101639500_B31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/asheducation-2014.1.210","article-title":"Guidelines for quantifying iron overload","volume":"2014","author":"Wood","year":"2014","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"19","key":"2019120610101639500_B32","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2009-06-225615","article-title":"Pancreatic iron loading predicts cardiac iron loading in thalassemia major","volume":"114","author":"Noetzli","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2019120610101639500_B33","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/asheducation-2014.1.450","article-title":"Red cell exchange: special focus on sickle cell disease","volume":"2014","author":"Kim","year":"2014","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"25","key":"2019120610101639500_B34","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1182\/blood-2014-07-586677","article-title":"Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload","volume":"125","author":"Aydinok","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2019120610101639500_B35","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/bjh.12340","article-title":"Assessment and management of iron overload in \u03b2-thalassaemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project","volume":"161","author":"Piga","year":"2013","journal-title":"Br J Haematol"},{"issue":"Pt A","key":"2019120610101639500_B36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.freeradbiomed.2015.07.019","article-title":"Iron and oxidative stress in cardiomyopathy in thalassemia","volume":"88","author":"Berdoukas","year":"2015","journal-title":"Free Radic Biol Med"},{"issue":"21","key":"2019120610101639500_B37","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V122.21.2257.2257","article-title":"Deferasirox\u2013deferoxamine combination therapy reduces cardiac iron with rapid liver iron removal in patients with severe transfusional iron overload (HYPERION)","volume":"122","author":"Aydinok","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2019120610101639500_B38","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1365-2141.2011.08626.x","article-title":"Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies","volume":"154","author":"Voskaridou","year":"2011","journal-title":"Br J Haematol"},{"key":"2019120610101639500_B39","first-page":"1","volume-title":"Guidlines for management of transfusion dependant thalassemia, vol. 20","author":"Cappellini","year":"2014"},{"issue":"3","key":"2019120610101639500_B40","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/bjh.12517","article-title":"Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major","volume":"163","author":"Origa","year":"2013","journal-title":"Br J Haematol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2019\/1\/337\/1546219\/hem2019000036c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2019\/1\/337\/1546219\/hem2019000036c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T07:07:10Z","timestamp":1722150430000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2019\/1\/337\/422629\/Iron-overload-in-transfusiondependent-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,6]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2019000036","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,6]]}}}